BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/28/2015 11:46:00 AM | Browse: 1172 | Download: 1756
 |
Received |
|
2015-03-24 17:34 |
|
Peer-Review Started |
|
2015-03-26 17:45 |
|
To Make the First Decision |
|
2015-05-18 12:39 |
|
Return for Revision |
|
2015-05-19 16:58 |
|
Revised |
|
2015-05-26 11:22 |
|
Second Decision |
|
2015-07-27 20:09 |
|
Accepted by Journal Editor-in-Chief |
|
2015-07-29 09:33 |
|
Accepted by Executive Editor-in-Chief |
|
2015-08-31 16:03 |
|
Articles in Press |
|
2015-08-31 16:03 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-09-09 17:31 |
|
Publish the Manuscript Online |
|
2015-09-28 11:42 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu-Yun Shao, Chih-Hung Hsu and Ann-Lii Cheng |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Science Council, Taiwan |
NSC-101-2314-B-002-141 |
| National Science Council, Taiwan |
NSC-102-2314-B-002-120 |
| Ministry of Science and Technology, Taiwan |
MOST-103-2314-B-002-181-MY2 |
| Ministry of Science and Technology, Taiwan |
MOST-103-2314-B-002-090 |
| Ministry of Science and Technology, Taiwan |
MOST -103-2314-B-002-092 |
|
| Corresponding Author |
Chih-Hung Hsu, MD, PhD, Department of Oncology, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10002, Taiwan. chihhunghsu@ntu.edu.tw
|
| Key Words |
Hepatocellular carcinoma; Predictive marker; Prognosis; Sorafenib |
| Core Tip |
A predictive biomarker of sorafenib efficacy in advanced hepatocellular carcinoma is a clinical unmet need. Previous studies identified the potential of blood levels of angiopoietin-2, hepatocyte growth factor, insulin-like growth factor-1, and transforming growth factor-β1 for predicting sorafenib efficacy. Alpha-fetoprotein response, dynamic contrast-enhanced magnetic resonance imaging, and treatment-related side effects may serve as early surrogate markers. Novel approaches based on super-responders or experimental mouse models may provide new research directions. A group effort that considers various prognostic factors and proper collection of tumor tissues before treatment is imperative for the success of future biomarker research in advanced hepatocellular carcinoma.
|
| Publish Date |
2015-09-28 11:42 |
| Citation |
Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol 2015; 21(36): 10336-10347 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i36/10336.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i36.10336 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
